Zehna Therapeutics Inc
Camilla Veronica Simpson is an accomplished professional in the biotechnology and pharmaceutical industries, currently serving as the Chief Executive Officer of Zehna Therapeutics Inc., which focuses on developing novel small molecule inhibitors for chronic kidney and cardiovascular diseases. In addition to this role, Camilla holds independent board member positions at GRI Bio, Inc. and Dyve Biosciences, and serves as Managing Member and President of Rare Strategic, LLC, advising early-stage companies across various therapeutic modalities. With extensive experience at BioMarin Pharmaceutical Inc. and Shire Pharmaceuticals, where Camilla led global regulatory strategies and product portfolio development, Camilla has a strong background in drug development and regulatory affairs. Camilla's educational qualifications include a BSc in Science from the University of Galway, an MSc with Distinction in Analytical Chemistry from Birkbeck, University of London, and a BSc Hons in Chemistry from Kingston University.
This person is not in any teams
This person is not in any offices
Zehna Therapeutics Inc
Zehna Therapeutics is an early stage biotech company developing non-bacteriocidal inhibitors of selected gut-microbial pathways clinically and mechanistically linked with chronic metabolic diseases. Our compounds inhibit the gut microbial enzyme CutC, preventing the conversion of dietary choline to trimethylamine and subsequently to trimethylamine N-oxide within the host. High systemic levels of trimethylamine N-oxide have been linked to accelerated development of both cardiovascular and chronic kidney disease, as demonstrated in large-scale clinical cohort studies. Chronic Kidney Disease (CKD) is our lead indication.